Nephroprotective effect of pioglitazone in a Wistar rat model of adenine‑induced chronic kidney disease

• Published in: Experimental and therapeutic medicine Vol. 28; no. 4; p. 392
• Main Authors: Pérez-Villalobos, Mariana Cecilia, Barba-González, Andrea, García-Carrillo, Nicté, Muñoz-Ortega, Martín Humberto, Sánchez-Alemán, Esperanza, Ávila-Blanco, Manuel Enrique, Morones-Gamboa, Jorge Christopher, Ventura-Juárez, Javier, Martínez-Hernández, Sandra Luz
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.10.2024; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Chronic kidney failure; Collagen; Diabetes; Diabetic nephropathy; Drug therapy; Extracellular matrix; Fatty acids; Gene expression; Glucose; Health aspects; Hypertension; Hypoglycemic agents; Insulin; Kidney diseases; Laboratory animals; Life expectancy; Mediation; Metabolism; Oxidation; Pharmaceutical industry; Population; Prevalence studies (Epidemiology); Smooth muscle; Sodium; Transforming growth factors; Type 2 diabetes; Urea; Uric acid; Weight control; Mexico; Germany; anti-inflammatory; chronic kidney disease; pioglitazone; fibrosis; adenine
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2024.12681

Chronic kidney disease (CKD) is a progressive disease with a high mortality rate and a worldwide prevalence of 13.4%, triggered by various diseases with high incidence. The aim of the present study was to investigate the anti-inflammatory and antifibrotic effect of pioglitazone on kidney in an adenine-induced Wistar rats and the mechanisms possibly involved. CKD was induced in 40 rats. Rats were divided into two groups, which were split into the following sub-groups: i) Therapeutic (pioglitazone administered after renal damage) divided into intact (healthy), adenine (CKD) and adenine/pioglitazone (treatment) and ii) prophylactic (adenine and pioglitazone administered at the same time) split into intact (healthy), adenine (CKD), endogenous reversion (recovery without treatment), adenine/pioglitazone (treatment) and pioglitazone sub-groups. Reverse transcription-quantitative PCR (collagen I, α-SMA and TGF-β), and hematoxylin-eosin, Masson's trichrome and Sirius red staining were performed to measure histological markers of kidney damage, also the serum markers (urea, creatinine and uric acid) were performed, for analyze the effects of pioglitazone. In the adenine/pioglitazone rats of the therapeutic group, renal function parameters such as eGFR increased and serum creatinine decreased from those of untreated rats (CKD), however the renal index, serum urea, abnormalities in renal morphology, inflammatory cells and relative gene expression of collagen I, α-SMA and TGF-β did not change relative to the CKD rats. In adenine/pioglitazone rats, extracellular matrix collagen accumulation was significantly lower than the CKD rats. On the other hand, in adenine/pioglitazone rats of the prophylactic group, the renal index, creatinine, urea, uric acid serum and relative gene expression of collagen I, α-SMA, and TGF-β were significantly lower, as well as the presence of 2,8-dihydroxyadenine crystals, and extracellular matrix collagen compared with CKD rats. In addition, the eGFR in the treatment group was similar to healthy rats, renal morphology was restored, and inflammatory cells were significantly lower. In conclusion, pioglitazone has a nephroprotective effect when administered in the early stages of kidney damage, reducing inflammatory and fibrotic processes and improving glomerular filtration rate. Furthermore, in the late phase of treatment, a tendency to decrease creatinine and increase eGFR was observed.